The Scripps Research Institute and Aileron Therapeutics™ today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide™ technology. The agreement provides Aileron exclusive worldwide rights to utilize Click chemistry for therapeutics and non-exclusive worldwide rights for diagnostics with Aileron's stabilized peptide and protein technology platforms. The novel Click chemistries subject to this agreement were developed by Nobel Laureate K. Barry Sharpless, Ph.D., the W.M. Keck Professor of Chemistry at Scripps Research.
“This agreement with Scripps Research further expands our arsenal to create novel therapeutics, including protein and non-helical peptide therapeutics, and will give us access to one of the top biomedical research organizations in the world.”
Aileron's Stapled Peptide™ technology is a breakthrough solution to drug potentially thousands of as-yet intractable disease targets, including those originating from long sought-after intracellular protein-protein interactions. The relationship with Scripps Research and the acquisition of this groundbreaking "Click" chemistry patent estate further establishes Aileron as the global leader in stabilized peptides and proteins.
"Aileron has discovered how to enable, and more importantly where to use, certain peptide and protein macrocyclization chemistries to drive therapeutic product profiles," said Tomi Sawyer, Ph.D., Chief Scientific Officer and Senior VP of Drug Discovery and Innovative Technologies at Aileron. "This agreement with Scripps Research further expands our arsenal to create novel therapeutics, including protein and non-helical peptide therapeutics, and will give us access to one of the top biomedical research organizations in the world."
Research reveals only a few brain regions remain untouched by transition to motherhood